Eli Lilly and Company

(New York Stock Exchange)
Back to all articles
Somewhat Bullish +45

Eli Lilly and Company (LLY)’s Weight-Loss Pill Just Won Its First Race in Europe. Novo Nordisk A/S (NVO) Still Has a Head Start

AI-generated analysis

πŸ‡¬πŸ‡§ Eli Lilly's Foundayo received UK approval on August 10 as the first European drug cleared for both weight management and type 2 diabetes.

🍽️ Foundayo offers a distinct convenience advantage over Novo Nordisk's Wegovy by allowing administration without food or water restrictions.

πŸ’° The new drug generated $98 million in US sales last quarter, prompting LLY to raise its 2026 revenue guidance to $85-$87 billion.

πŸ“‰ UK adoption is expected to be slower than Wegovy's initial US launch due to pending NHS cost-effectiveness reviews and the need to build brand trust.

βš–οΈ Novo Nordisk maintains a significant head start in European markets with over 5 million total prescriptions for Wegovy since its January launch.

πŸ“‰ Novo Nordisk shares dropped nearly 6% after reporting Q2 sales that missed analyst expectations and citing tougher US competition.

βš”οΈ The competitive rivalry has escalated, with Novo Nordisk filing a lawsuit against Eli Lilly over alleged deceptive advertising practices.

🏦 Hedge fund ownership of LLY decreased slightly to 132 holders in Q1 2026, though it remains more widely held than Novo Nordisk.

Bullish Signals
  • Foundayo won approval in the UK as the first European drug cleared for both weight management and type 2 diabetes.
  • The new pill offers a unique convenience edge by allowing patients to take it at any time without food or water restrictions, unlike competitors requiring empty stomachs.
  • Foundayo brought in $98 million in US sales last quarter, driving an upward revision of 2026 revenue guidance to $85 billion to $87 billion.
  • The drug is priced below Mounjaro's roughly Β£330 monthly list price for the upcoming UK private prescription launch.
Risk Factors
  • Adoption of Foundayo in the US has been slower than Wegovy, reflecting the time needed to build trust with doctors and patients.
  • NHS access in the UK is not automatic and depends on a pending cost-effectiveness review, limiting early patient access to private payers.
  • The drug remains under review by the European Union while competitor Wegovy has already secured a positive recommendation there.
  • Novo Nordisk has sued Eli Lilly over allegedly deceptive advertising, highlighting intense competitive friction in the weight-loss market.
Full Analysis
Eli Lilly and Company (LLY) achieved a significant regulatory milestone with its weight-loss pill, Foundayo, receiving approval in the United Kingdom on August 10. This marks the first European country to clear the drug for both weight management and type 2 diabetes, positioning it as the second GLP-1 pill approved in Europe following Novo Nordisk's Wegovy. The UK launch is scheduled for later in the month via private prescriptions, with pricing set below Mounjaro's list price. The article highlights a key competitive advantage for Foundayo: unlike Novo Nordisk's Wegovy, which requires taking on an empty stomach with a 30-minute wait before eating, Foundayo can be taken at any time without food or water restrictions. This convenience factor is central to Lilly's strategy to capture market share in the growing European obesity treatment sector. Financially, Foundayo generated $98 million in US sales during the last quarter, contributing to an upward revision of LLY's 2026 revenue guidance to between $85 billion and $87 billion. However, adoption in the UK is expected to be slower than Wegovy's initial US performance due to the time required to build trust with prescribers and pending cost-effectiveness reviews by the NHS. While Novo Nordisk maintains a substantial lead in European prescription volumes and recently reported strong second-quarter sales growth despite missing specific analyst expectations for Wegovy, LLY remains widely held by hedge funds. The rivalry has intensified, evidenced by Novo's lawsuit against Lilly regarding alleged deceptive advertising.